$400 Million in New Venture Capital Money

May 27, 2011

By: Melissa M. Turczyn

On Thursday, May 5th, legislation was revealed by its main sponsors, Sen. Randy Hopper and Rep. Gary Tauchen, which would aid the venture capital community in Wisconsin. The “Wisconsin Jobs Act,” is a bill that would create two new complementary funds in Wisconsin – the Jobs Now Fund and the Badger Jobs Fund. The two funds combined would total up to $400 million.

The Jobs Now Fund would be a rapid-response fund, which would issue $200 million in tax credits over time to certain insurance companies that made investments in certified capital funds. The actual tax credits would be for 80% of the value of the investments made. In other words, the $200 million in tax credits could potentially attract up to $250 million in investments. The credits would not be able to be claimed for a minimum of five years, thereby insuring that the money would be invested long before the credits would be paid.

The Badger Jobs Fund, on the other hand, would be a longer term program. This fund would operate as a “fund of funds,” meaning it would invest up to $200 million in qualified venture capital funds. The money would come from the placement of bonds, which would be supported by investment returns, the growth of aggregate state tax collections from the companies financed by such venture capital funds, and contingent tax credits. Each qualified venture capital fund would be limited to no more than 15% of the entire pool of funds. Additionally, for each $1 a VC fund received from the Fund, it would need to raise at least $3 on its own.

The bill also contains certain governance provisions, criteria for eligible companies and investors and accountability standards.

It is estimated that some thirty other states have already enacted programs similar to the proposed Wisconsin Jobs Act. Given the success Wisconsin has had with its Act 255 Tax Credits, it appears we are fashionably late to the party in further developing the infrastructure necessary to help our home-grown high-growth companies.


Is Quicker Really Better? The Overhaul of the 510(k) Process

March 7, 2011

By: Melissa M. Turczyn

On January 19, 2011, the Food and Drug Administration (the “FDA”) announced 25 steps it intends to take before year end to improve the agency’s 510(k) clearance program for medical devices. The purpose of the program is to allow medical devices to be marketed if the applicant can show that the device is substantially equivalent to a device already on the market.

In recent years, the FDA has come under increasing scrutiny by both medical device companies and outspoken critics who claimed the current process was inconsistent and slow, and has resulted in unsafe devices being cleared. The newly released action items, selected from a broader group which included more controversial proposals, are intended to speed along the approval process for medical devices (with most devices being cleared in roughly five months), while maintaining a commitment to public safety.

Action Items to be Completed before December 31, 2011:

1.The FDA will create Draft Guidance for each of the following, beginning June 15, 2011:

a. 510(k) Modifications;

b. Clinical Trials;

c. Evaluation of Automatic Class III Designations (De Novo);

d. Standards;

e. Appeals;

f. 510(k) Paradigm;

g. Pre-Submission Interactions; and

h. Product Codes.

2.  Beginning March 31, 2011, the FDA will modify certain internal and administrative matters, including the establishment of a Center Science Council, the enhancement of training provided to its internal staff and the development of a network of external experts to leverage scientific expertise found in the outside marketplace.

3.  Also beginning March 31, 2011, the FDA will begin certain programmatic and regulatory initiatives to implement new programs and improve existing processes. For example, a public meeting will be held on April 7th and 8th to provide additional information about the viewing of device photos in a public database without the disclosure of any unique proprietary information of the devices.

The Institute of Medicine (the “IOM”) is also conducting an independent evaluation of the process and will provide feedback to the FDA on certain controversial issues, including the scope and grounds for rescinding a 510(k) clearance, providing greater authority for postmarket surveillance, and providing clarification on when a device should no longer be available for use as a predicate.

Although early commentators are encouraged by the proposed changes, the action items are still only proposals, meaning the final look and operation of the 510(k) clearance process remain to be seen.


Act 255 Tax Credit Changes in 2011

December 1, 2010

By: Melissa M. Turczyn

As companies franticly scramble to get all of their ducks in a row before the clock strikes midnight on December 31st, including doling out any remaining Act 255 Tax Credits, perhaps we should take a minute to recap the upcoming changes to the credits, and discuss what investors can expect as we move into 2011.

Tax Credit Limitation Increases

The first big change involves the current tax credit limitations. Assuming a company has been approved by the Wisconsin Department of Commerce (the “Department”) as a Qualified New Business Venture (“QNBV”), such company can now take up to $8,000,000 in qualified investments. Such limitation is double the current limit of $4,000,000.  In other words, a QNBV may now qualify for tax credits for up to $8,000,000 of funding it receives. Given the state of the economy, this will likely aid many existing companies who must now go back to investors to ask for additional money.

Another limitation increase allows angel investors to invest substantially more money in QNBVs annually. Currently, there is a maximum of $5,500,000 allowed. Starting on January 1st, that limit goes up to $18,000,000; meaning an angel investor can invest up to that amount in QNBVs and receive tax credits assuming the portfolio companies have credits to allocate. It is important to note that there will be an additional $250,000 of tax credits available for investments in nanotechnology businesses.

A similar limitation increase is provided to fund managers. Instead of the current $6,000,000 maximum annual investment, fund managers may now invest up to $18,500,000 annually. An additional $250,000 tax credit is also available for investments made in nanotechnology businesses.

Capital Gains

If the increases in tax credit limitations are the ice cream sundae, perhaps the Governor’s latest announcement is the cherry on the top. Beginning January 1, 2011, investors with long-term capital gains will be able to subtract such gains from their federal adjusted gross income, assuming they are able to clear a few low hurdles. Similar to the Act 255 Tax Credits, the Department must approve a business as a QNBV Cap Gains Company. The definition for the Cap Gains Companies is broader than the original QNBV definition so as to allow more companies to qualify.

After a company is qualified under this program, it may seek out investors who are looking to ditch up to an aggregate of $10,000,000 of long-term capital gains per year. The process goes as follows: the investor sells the assets which provide the long-term capital gain; the investor must then deposit such gain into a segregated account in a financial institution; within 180 days of the sale, the investor must invest ALL OF THE PROCEEDS in a QNBV Cap Gains Company; and then the investor must notify the Wisconsin Department of Revenue that it will not be declaring that gain on its income tax return. What a great way to say Happy Holidays to the Department of Revenue.


Top Legal Mistakes Entrepreneurs Make: 83(b) Elections

August 19, 2010

By: Melissa M. Turczyn

Key employees of start-up companies will typically hold their shares of common stock in the form of restricted stock, subject to certain vesting criteria. In essence, this means that a set number of shares will vest upon the happening of future events, lengthening the amount of time it takes for the employees to have full ownership of their shares in the company. Investors often require this type of arrangement, as it provides a continuing incentive to make the company successful.

Under certain tax laws, shares which are not fully vested will be treated as having a substantial risk of forfeiture, meaning the employee’s rights in the stock are conditioned upon one or more future events. If an employee leaves the company for any reason, prior to the time all shares of his stock vest, the employee will forfeit any rights he has to the unvested shares. As a result of this possibility, the IRS does not tax the employee upon the initial issuance of the restricted shares. More specifically, the employee will not pay tax until the restricted shares actually vest, at which point the employee will pay tax on the fair market value of the stock at that time. While this delay in paying taxes may seem like a good outcome, in actuality, it can cost the employee a lot more money down the road.

Presumably, the employee believes the company is going to be wildly successful in the near to mid future. If that is the case, the company is going to be worth multiples of what it was worth when the restricted shares were actually issued. This increase in the valuation of the company is going to lead to an increase in the amount of tax the employee will pay, once his shares actually vest. So the IRS gives the employee the option to pay his taxes early, when the stock will likely have a lower valuation, by filing a tax election referred to as an “83(b) election”. In addition, if the employee elects to file an 83(b) election, the capital gains period will start on the date the restricted shares are issued, as opposed to the date the stock vests, giving the employee a jump start on the one-year holding period for long term capital gains treatment.

To take advantage of this opportunity, the employee must submit an 83(b) election to the IRS within thirty days of the date of issuance of the restricted shares of stock. There does not appear to be any extension allowed for this time period, so it is imperative that the employee submit his election within the first thirty days. The election is made by submitting one copy of a written statement to the specific internal revenue office with which the employee files his individual income tax returns. Copies of the election will also need to be submitted (i) with the employee’s income tax return for the taxable year in which the shares are issued, and (ii) to the company.

Taking into account all of the above, what is the downside of filing an 83(b) election? First, such an election is not revocable (with very limited exceptions). So if the vesting criteria are not satisfied, the employee will likely have paid a higher amount of taxes than he would have otherwise paid. If this happens, the employee is unable to revoke the election or receive a refund from the IRS. Additionally, if the valuation of the company actually decreases before an employee’s shares have fully vested, he will likely have paid a higher amount of taxes. Again, he can not revoke the election or request a refund. In most cases, however, these risks are not strong enough to defer an entrepreneur from having full faith in his company, and in making the 83(b) election.


Follow

Get every new post delivered to your Inbox.

Join 40 other followers